Patents by Inventor Roland B. Stoughton
Roland B. Stoughton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11781187Abstract: The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.Type: GrantFiled: November 16, 2018Date of Patent: October 10, 2023Assignees: The General Hospital Corporation, GPB Scientific, LLC, Verinata Health, Inc.Inventors: Daniel Shoemaker, Mehmet Toner, Ravi Kapur, Roland B. Stoughton, Ronald W. Davis
-
Publication number: 20210062261Abstract: The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.Type: ApplicationFiled: November 16, 2018Publication date: March 4, 2021Inventors: Daniel Shoemaker, Mehmet Toner, Ravi Kapur, Roland B. Stoughton, Ronald W. Davis
-
Patent number: 10155984Abstract: The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.Type: GrantFiled: April 27, 2015Date of Patent: December 18, 2018Assignees: The General Hospital Corporation, GPB Scientific, LLC, Verinata Health, Inc.Inventors: Daniel Shoemaker, Mehmet Toner, Ravi Kapur, Roland B. Stoughton, Ronald W. Davis
-
Patent number: 9273355Abstract: The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.Type: GrantFiled: March 14, 2013Date of Patent: March 1, 2016Assignees: The General Hospital Corporation, GPB Scientific, LLC, Verinata Health, Inc.Inventors: Daniel Shoemaker, Ravi Kapur, Mehmet Toner, Roland B. Stoughton, Ronald W. Davis
-
Publication number: 20150232936Abstract: The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.Type: ApplicationFiled: April 27, 2015Publication date: August 20, 2015Inventors: Daniel Shoemaker, Mehmet Toner, Ravi Kapur, Roland B. Stoughton, Ronald W. Davis
-
Publication number: 20130295565Abstract: The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventors: DANIEL SHOEMAKER, Ravi Kapur, Mehmet Toner, Roland B. Stoughton, Ronald W. Davis
-
Publication number: 20120095696Abstract: Rapid and definitive bioagent detection and identification can be carried out without nucleic acid sequencing. Analysis of a variety of bioagents and samples, such as air, fluid, and body samples, can be carried out to provide information useful for industrial, medical, and environmental purposes. Nucleic acid samples of unknown or suspected bioagents may be collected, optimal primer pairs may be selected, and the nucleic acid may be amplified. Expected mass spectra signal models may be generated and selected, the actual mass spectra of the amplicons may be obtained. The expected mass spectra most closely correlating with the actual mass spectra may be determined using a joint maximum likelihood analysis, and base counts for the actual mass spectra and the expected mass spectra may be obtained. The most likely candidate bioagents may then be determined.Type: ApplicationFiled: September 23, 2011Publication date: April 19, 2012Applicant: IBIS BIOSCIENCES, INC.Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Dino J. Sofianos, Karl H. Rudnick, Duane J. Knize, Roland B. Stoughton, Cecil L. Basham, JR., Clifford T. Lewis, Brons M. Larson, Jonathan R. Bar-on, Dennis P. Murray, David W. Robbins, John P. Penhune
-
Patent number: 8046171Abstract: Rapid and definitive bioagent detection and identification can be carried out without nucleic acid sequencing. Analysis of a variety of bioagents and samples, such as air, fluid, and body samples, can be carried out to provide information useful for industrial, medical, and environmental purposes. Nucleic acid samples of unknown or suspected bioagents may be collected, optimal primer pairs may be selected, and the nucleic acid may be amplified. Expected mass spectra signal models may be generated and selected, the actual mass spectra of the amplicons may be obtained. The expected mass spectra most closely correlating with the actual mass spectra may be determined using a joint maximum likelihood analysis, and base counts for the actual mass spectra and the expected mass spectra may be obtained. The most likely candidate bioagents may then be determined.Type: GrantFiled: April 18, 2003Date of Patent: October 25, 2011Assignee: Ibis Biosciences, Inc.Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Dino J. Sofianos, Karl H. Rudnick, Duane J. Knize, Roland B. Stoughton, Cecil L. Basham, Jr., Clifford T. Lewis, Brons M. Larson, Jonathan R. Bar-on, Dennis P. Murray, David W. Robbins, John P. Penhune
-
Publication number: 20040209260Abstract: Rapid and definitive bioagent detection and identification can be carried out without nucleic acid sequencing. Analysis of a variety of bioagents and samples, such as air, fluid, and body samples, can be carried out to provide information useful for industrial, medical, and environmental purposes. Nucleic acid samples of unknown or suspected bioagents may be collected, optimal primer pairs may be selected, and the nucleic acid may be amplified. Expected mass spectra signal models may be generated and selected, the actual mass spectra of the amplicons may be obtained. The expected mass spectra most closely correlating with the actual mass spectra may be determined using a joint maximum likelihood analysis, and base counts for the actual mass spectra and the expected mass spectra may be obtained. The most likely candidate bioagents may then be determined.Type: ApplicationFiled: April 18, 2003Publication date: October 21, 2004Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Dino J. Sofianos, Karl H. Rudnick, Duane J. Knize, Roland B. Stoughton, Cecil L. Basham, Clifford T. Lewis, Brons M. Larson, Jonathan R. Bar-on, Dennis P. Murray, David W. Robbins, John P. Penhune
-
Patent number: 6297024Abstract: Methods for measuring in vivo activation of the lectin pathway by measuring mannan-binding serine protease activity (MASP) are provided. The methods are accomplished by C3a and C4a levels in in vitro activated EDTA plasma. In particular, the increase in C3a and/or C4a as a function of time is an indicator of the amount of activated MASP in EDTA plasma. Methods are also provided for measuring the alternate and classical pathways of complement activation, exclusive of the lectin pathway, and thereby disorders associated therewith. To perform such measurements, Futhan or other serine protease inhibitor is added to blood or plasma, containing a divalent metal ion chelator, and C3a and C4a are measured.Type: GrantFiled: February 5, 1999Date of Patent: October 2, 2001Assignees: Cell Activation, Inc., The Scripps Research InstituteInventors: Tony E. Hugli, Roland B. Stoughton